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Applying results from clinical trials: tranexamic
acid in trauma patients
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Abstract
This paper considers how results from clinical trials should be applied in the care of patients, using the results of
the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2) trial of tranexamic acid in
bleeding trauma patients as a case study. We explain why an understanding of the mechanisms of action of the
trial treatment, and insight into the factors that might be relevant to this mechanism, is critical in order to properly
apply (generalise) trial results and why it is not necessary that the trial population is representative of the
population in which the medicine will be used. We explain why cause (mechanism)-specific mortality is more
generalizable than all-cause mortality and why the risk ratio is the generalizable measure of the effect of the
treatment. Overall, we argue that a biological insight into how the treatment works is more relevant when applying
research results to patient care than the application of statistical reasoning.
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Introduction
In September 1962, writing in the Keio Journal of Medi-
cine, Japanese researchers Shosuke and Utako Okamoto
reported the invention of a new chemical entity that
inhibited the enzymatic breakdown of fibrin by plasmin
[1]. Initially referred to as AMCHA, this drug is now
known as tranexamic acid. Tranexamic acid is a syn-
thetic analogue of the amino acid lysine. It can be ad-
ministered orally or by a short intravenous infusion after
which peak plasma concentrations of tranexamic acid
are obtained rapidly. It is excreted as unchanged drug in
the urine with an elimination half-life of about 3 h.
The Clinical Randomisation of an Antifibrinolytic in
Significant Haemorrhage (CRASH-2) trial was a rando-
mised controlled trial of the effect of tranexamic acid on
death and vascular occlusive events in bleeding trauma
patients. The results were published in 2010 [2]. A total
of 20,211 adult trauma patients with significant bleeding,
who were within 8 h of their injury, were randomly allo-
cated to receive tranexamic acid (TXA, 1 g over 10 min
followed by an infusion of 1 g over 8 h) or matching
placebo. The primary outcome was death in the hospital
within 4 weeks. TXA significantly reduced death due to
bleeding (RR = 0.85, 95% CI 0.76–0.96) and all-cause
mortality (RR = 0.91, 95% CI 0.85–0.97), with no in-
crease in vascular occlusive events. The reduction in
death due to bleeding was greatest when TXA was given
within 3 h of injury, (RR = 0.72, 95% CI 0.63–0.83) [3].
When TXA was given after 3 h, there was no mortality
reduction. On the basis of these results, TXA was added
to the WHO List of Essential Medicines and included in
trauma protocols around the world.
If clinical trial results could not be applied (general-
ised) to people who did not take part in the trial, there
would be little reason to do them. If a trial shows con-
vincingly that a treatment reduces the risk of an adverse
health outcome in one group of patients, we have to
consider what effect it might have in another group of
patients. Since the publication of the CRASH-2 results,
there has been considerable discussion about how TXA
should be used in practice. Some authors, pointing out
that most of the patients in the CRASH-2 trial were re-
cruited from hospitals in Africa, Asia and Latin America,
question whether the results are applicable to ‘modern’
trauma care systems and call for further trials before
implementing the results [4]. Others suggest limiting
TXA use to specific patient subgroups, such as those with
low blood pressure or laboratory evidence of ‘hyperfibrino-
lysis’ [5,6]. This paper considers some pathophysiological
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and epidemiological issues relevant to the application of
the CRASH-2 trial results.
Review
How should we apply the results from the CRASH-2 trial?
Some clinicians believe that a treatment should only be
used in patients similar to those included in the trial (or
trials) that showed the treatment to be effective. In their
paper ‘Tranexamic acid in trauma: How should we use
it?’ Neapolitano et al. recommend that TXA is used only
in adult trauma patients, presumably because only adults
were included in the CRASH-2 trial [6].Their advice is
not without potential consequences. Every year, world-
wide, tens of thousands of children bleed to death after
trauma and if TXA is also safe and effective in children,
it could prevent hundreds of child deaths. Similarly, in
arguing for a new trial of TXA in Australasian patients,
Gruen et al. point out that many of the patients in
CRASH-2 trial were from middle income countries and
‘because substantial differences are likely between ad-
vanced and less developed trauma systems, hypotheses
about TXA should be reinvestigated.’ Gruen calls for
more evidence on the benefits and risks of TXA in
patients treated to ‘modern civilian and military trauma
standards’ [4].
We do not deny the existence of international differ-
ences in trauma care, but this does not necessarily mean
that results obtained in one setting cannot be applied in
another. Nor does the failure to include children in the
CRASH-2 trial mean that the results cannot be general-
ised to children. The view that generalisation is a simple
extrapolation from a trial population to a patient popula-
tion confuses statistical and scientific inference [7].
Whereas statistical inference, the process of using sample
information to make inferences about the population from
which it was drawn, is helped by having a representative
sample; scientific inference involves making valid conclu-
sions about how biology works, and important insights
into the effects of drugs can be obtained from patients that
are completely unrepresentative of the patients in which
the drug might be used. Children were excluded from the
CRASH-2 trial, not because the investigators did not
intend the results to be applied in children, but because it
is logistically difficult to conduct large trials that include
children, especially in emergency situations. For example,
using a fixed dose of a treatment is more practical than a
body weight-related dose. With a fixed dose, treatment in-
structions can be simplified and there is no need to weight
the patient and make a calculation, which in an emergency
is time consuming and error prone. However, fixed doses
cannot be used in children, and so the most efficient way
to obtain valid and precise estimates of the effect of TXA
in people of all ages was to conduct a large trial that
excluded children.
To generalise results, we must consider the likely
mechanism by which the treatment affected the health
outcome and the factors that might be relevant to this
mechanism [7]. The observation, made in 1954, that
smoking increases mortality in male British doctors, was
readily extrapolated to smokers in general, even though
the doctors studied were unrepresentative of a wider
population in terms of sex, age, social class and ethnicity
[8]. Being male, being British and being a doctor are
not relevant to the biological effect of smoking. Simi-
larly, when deciding which trauma patients should be
treated with TXA, we must consider how TXA reduces
the risk of death due to bleeding and what patient
characteristics might be relevant to the mechanism of
action. Is there any biological reason why TXA might
work differently in children or in patients receiving
‘modern’ trauma care?
Mechanism of action of tranexamic acid
The best evidence that TXA reduces bleeding is from
randomised controlled trials of TXA in surgery where,
unlike trauma, bleeding can be measured reasonably
accurately. A 2012 systematic review and meta-analysis,
which included data from 104 trials with a total of 8,030
patients, showed that TXA reduces bleeding by about
one third (pooled ratio = 0 · 66, 95% CI 0 · 65–0 · 67;
P < 0 · 001) regardless of the type of surgery and the
extent of bleeding [9,10]. There were also fewer deaths
in TXA-treated patients (0.61, 0.38–0.98; P = 0.04),
although when the analysis was restricted to trials using
adequate allocation concealment there was more uncer-
tainty (0.67, 0.33–1.34; P = 0.25).
Tranexamic acid reduces bleeding by inhibiting the
enzymatic breakdown of fibrin blood clots. Plasminogen,
a glycoprotein pro-enzyme produced by the liver, is
converted into the fibrinolytic enzyme plasmin by tissue
plasminogen activator (TPA). The plasminogen molecule
is folded into loops called kringles that protrude like fin-
gers. Plasminogen binds to fibrin via lysine-binding sites
situated on the tips of the kringles [11,12]. If the lysine
residues on fibrin are enzymatically removed, the binding
of plasminogen is inhibited. Fibrin binds both plasmino-
gen and TPA thus localizing and enhancing plasmin
formation [11]. Plasmin that is bound to fibrin is also less
susceptible to plasmin inhibitors. Plasmin splits fibrin into
fibrin degradation products. This exposes more lysine resi-
dues which bind more plasminogen, thus accelerating
fibrinolysis. TXA is a molecular analogue of lysine that in-
hibits fibrinolysis by reducing the binding of plasminogen
to fibrin.
Although new discoveries in molecular biology and
clinical research may elaborate the mechanism outlined
above, based on current knowledge, the causal chain
linking TXA to reduced mortality includes inhibition of
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plasminogen binding, less plasmin formation, decreased
fibrinolysis, less bleeding and fewer exsanguinations.
The question for doctors providing ‘modern’ trauma
care is what aspects of contemporary care are relevant
to this (or some other hypothesised) mechanism of
action? Although Gruen et al. mention ‘rapid access to
blood products, damage control surgery and angiog-
raphy, and advanced critical care’ as factors, they give no
biological reason why these treatments would affect the
mechanism of action of TXA such as to mitigate its ef-
fect. Similarly, is there any reason why TXA would stop
an 18-year old from bleeding to death but not an 8-year
old? A working group set up by the UK Royal College of
Paediatrics and Child Health, aware of the evidence that
TXA reduces bleeding in paediatric surgery, was pre-
pared to generalise the CRASH-2 trial results to paediat-
ric trauma [13]. They recommended that an adult TXA
dose is used in children over 12 and a weight-related
dose for younger children.
How much benefit should we expect from TXA treatment?
Do we generalise the risk difference or the risk ratio?
The CRASH-2 trial compared the risk of death in TXA
and placebo allocated patients. There are two commonly
used measures of the effect of treatments: the risk differ-
ence and the risk ratio. Neapolitano et al. focus on the risk
difference and are unimpressed: ‘What is critical is the
modest effect on the overall population: All-cause mortal-
ity was “significantly” reduced from 16.0%–14.5% (NNT,
67). The risk of death caused by bleeding overall was “sig-
nificantly” reduced from 5.7%–4.9% (NNT, 121)’ [6]. Their
concern is that a risk difference of only 0.8% (5.7%–4.9%),
whilst statistically significant might be clinically unimport-
ant. But is the risk difference a generalizable measure?
Figure 1 shows two hypothetical clinical trials. The
first compared the risk of death due to bleeding (red cir-
cles) in ten TXA-treated and ten control patients. There
were four deaths in the TXA group and six deaths in the
control group. The purpose of the control group in a
randomised controlled trial is to indicate what would
have happened in the absence of treatment. In this case,
two of the six patients (one third) who would have died
if untreated, were saved by TXA. In biological terms,
TXA blocked the pathophysiological mechanism leading
to death in one third of the patients who would other-
wise have died. The risk of death in the control and
TXA groups was 60% and 40%, respectively. The risk
difference is 20% and the risk ratio is 0.67. The second
trial compared the risk of death due to bleeding in 20
TXA-treated and 20 control patients. Again, there were
four deaths in the TXA group and six deaths in the
control group. Once again, two of the six patients who
would have died if untreated, were saved by TXA. The
biological effect is the same in both trials. The risk of
death in the control and TXA groups was 30% and 20%,
respectively. This time the risk difference is 10%,
although the risk ratio is again 0.67. The biological effect
of a treatment is indicated by the risk ratio. Indeed, the
relative risk reduction (1-risk ratio) is the proportion of
patients in whom the mechanism leading to death is
blocked by treatment.
When we generalise results, we do so on the basis that
the biological effect of treatment will be broadly similar
in the patients in whom the treatment will be used [7].
The risk ratio is therefore the generalizable measure. If
the number of patients is the same in the treated and
control groups, the risk ratio is simply the ratio of
outcome events in the two groups. Unsurprisingly, only
patients who experience the outcome can contribute
information on the effect of the treatment on that out-
come. The risk difference on the other hand, depends on
the number of patients who did not experience the out-
come. Furthermore, because there is no reason to expect
that any given patient would have the same baseline risk
as the patients in the trial, the risk difference is not
generalizable. The number needed to be treated, which
is the reciprocal of the risk difference, is also not
generalizable. Instead it should be calculated by applying
the risk ratio from the trial to the patient’s baseline risk.
If the baseline risk of death is estimated at 30% and the
risk ratio is two thirds (i.e. RR = 4/6), we would expect
20% of treated patients to die. The risk difference is 10%
and the number needed to treat is 10. When given soon
after injury, TXA reduces the risk of bleeding to death
by about a third. It would be hard to argue that a
one-third reduction in the risk of bleeding to death is
unimportant.
All-cause mortality or cause-specific mortality?
When given within one hour of injury, there was a sub-
stantial reduction in death due to bleeding (RR = 0.68)
that was highly statistically significant but no reduction
in non-bleeding deaths (RR = 1.04). There was also a
statistically significant reduction in all-cause mortality
(RR = 0.87). On the basis of these results, by how much
would we expect TXA to reduce mortality in other
trauma patients? Can we expect a similar reduction in
death from bleeding, all-cause mortality or in both of
these measures?
We have seen that the risk ratio for death is essentially
the ratio of deaths in the treated and control groups.
Figure 2 shows results from a hypothetical clinical trial
of treatment for bleeding. There is a one-third reduction
in deaths due to bleeding but no effect on other causes
of death. The effect on all-cause mortality is an average
of its effect on specific causes of death, weighted accord-
ing to the relative contributions of the specific causes.
In the CRASH-2 trial, 44% of deaths within an hour of
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injury were due to bleeding and 55% were from other
causes in the control group. The overall effect on
all-cause mortality is a weighted average of the effect on
bleeding and non-bleeding deaths: 0.68 × 0.44 + 1.04 ×
0.55 = 0.87. However, the relative contribution of causes
of death in the population in which the results are being
applied might be different to that in the trial. For
example, in the CRASH-2 trial data, about 60% of
patients with penetrating trauma died from bleeding
compared with 25% of patients with blunt trauma. Conse-
quently, the effect of TXA on all-cause mortality is not
generalizable. On the other hand, the effect of TXA on
death due to bleeding should be generalizable since this
reflects the biological mechanism of action of TXA which
we would expect to be broadly similar (i.e. generalizable)
in different patients.
Is tranexamic acid more or less effective in particular
groups of patients?
An awareness of the circumstances necessary for the valid
generalisation of treatment effects is the essence of thera-
peutic knowledge [14]. Subgroup analyses of clinical trials
can sometimes deepen our understanding of these cir-
cumstances and suggest whether the treatment is more
or less effective in particular patient groups. However,
subgroup analyses are often misleading. Chance alone
can produce spurious subgroup results that can lead to
patients being denied an effective treatment [15]. On
Figure 2 Hypothetical trial: effect on all-cause mortality is a weighted average of effect on cause-specific mortality. The treatment
reduces the risk of death due to bleeding by one third (RR = 0.67) but has no effect on other causes of death (RR = 1.0). The effect on all-cause
mortality (RR = 0.8) is a weighted average of its effect on deaths due to bleeding and on other causes of death, weighted according to the
relative contributions of the different causes.
Figure 1 Two hypothetical trials: the risk ratio is the generalizable measure of the effect of treatment. In both trials, the biological effect
of the treatment is the same, corresponding to a one third reduction in the risk of death. The relative risk is the same in both trials and reflects
the biological effect of the treatment. However, the risk difference is not the same. The relative risk is a generalizable measure of the biological
effect of a treatment, whereas the risk difference is not generalizable.
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biological grounds, we should expect treatments to have
broadly similar effects on a given outcome and should be
sceptical of claims that a treatment is beneficial in one
subgroup but harmful in another. Indeed, differential
subgroup effects are more credible if based on a sound
biological rationale that is precisely specified prior to data
analysis [15]. Patient characteristics can vary widely but
only those that are relevant to the mechanism by which
the drug prevents the particular adverse outcome should
lead to differential effects. What biological reason is there
to expect a larger or smaller proportion of outcome events
to be affected by the treatment? The risk of inappropriate
inferences can be reduced by using the overall relative risk
reduction in the trial as the best estimate of the likely
effect in each subgroup, only departing from this assump-
tion if there is strong evidence to the contrary. In other
words, the average biological effect of the treatment that
was observed in the trial (or meta-analyses of all relevant
trials) is the best guide to its effect in any particular
subgroup [15].
Although there was no evidence that the effect of
TXA varied according to baseline systolic blood pressure
(P = 0.33), after pointing out that ‘the signal for benefit
of TXA was in the most severe shock group as defined
by admission SBP’ Neapolitano and colleagues advised
that TXA is used only in patients ‘with severe haemor-
rhagic shock (SBP < 75 mm Hg)’ [6]. The focus on this
subgroup is hard to understand from a biological per-
spective and could have serious implications for patient
care. Since TXA reduces bleeding and early treatment is
most effective, it seems sensible to give TXA before the
blood pressure falls to dangerously low levels. TXA
appears to reduce the risk of death due to bleeding by
about one third, regardless of the patient’s baseline risk
[16]. If the patient’s risk of bleeding to death is 30%,
giving TXA should reduce the risk to about 20%; and if
the baseline risk is 3%, then TXA should reduce this to
about 2%. Because there are many more patients at low
risk, a policy of giving TXA to all bleeding trauma
patients would prevent more deaths than using it only in
the most severely injured. Indeed, using data from a
large UK-based trauma registry, we showed that if TXA
use is limited to patients with a baseline risk of more
than 20%, we would miss most of the benefit, since 53%
of TXA preventable deaths are in patients who had a
baseline risk of death of less than 20% [16].
In the CRASH-2 trial, we prespecified an analysis of the
effect of TXA by time from injury to the start of treatment
(<1, 1–3, 3–8 h). We hypothesised that TXA would be
most effective soon after injury, when bleeding is profuse,
and less effective later, when the acute phase response to
trauma increases the risk of thrombosis [17]. We found
strong evidence in support of our hypothesis (P < 0.0001).
In patients treated within 3 h, TXA substantially reduced
the risk of death due to bleeding but after 3 h, TXA
appeared to increase the risk of death due to bleeding [3].
Time from injury is almost certainly a proxy for a change
in the pathophysiological state of the patient relevant to
the mechanism by which TXA reduces bleeding. We think
this could be PAI-1-induced suppression of fibrinolysis
and the onset of thrombotic disseminated intravascular
coagulation (DIC) [18,19]. DIC is characterised by intra-
vascular activation of coagulation with widespread fibrin
deposition. Because TXA inhibits fibrinolysis, it could ex-
acerbate this process. Although the underlying pathology
is thrombosis, due to the consumption of coagulation fac-
tors, thrombotic DIC usually manifests as bleeding. This
might explain why TXA appeared harmful when initiated
after 3 h. Late treatment with TXA may have increased
the risk of thrombotic DIC. Among patients treated after
3 h, deaths apparently due to bleeding may have been
caused by intravascular thrombosis, a completely different
mechanism of death. Further research may help to explain
this striking subgroup result.
If we could identify only those patients who will bene-
fit from TXA treatment, we could avoid treating patients
unnecessarily. This understandable objective may ex-
plain why some authors recommend that TXA is used
only in patients with evidence of ‘hyperfibrinolysis’ on
thromboelastography [6,20]. After all, if TXA works by
inhibiting fibrinolysis, it should not be effective when
fibrinolysis is absent. However, fibrinolysis is not present
or absent, but present to varying degrees, and even pa-
tients with ‘normal’ levels of fibrinolysis may benefit
from TXA if this reduces bleeding [21]. The degree of
fibrinolysis is not the only factor that determines the risk
of death. The extent of the bleeding and other patient
factors are also important. Age is a strong risk factor for
death in trauma patients [22]. Older patients appear less
able to tolerate blood loss. Even a slight reduction in
bleeding could prevent death in patients who are at high
risk for other reasons. Trials of TXA in surgery show
that TXA reduces bleeding by about one third even
when bleeding is modest [10]. The challenge for clini-
cians is not to identify patients with ‘hyperfibrinolysis’,
but to identify patients at risk of bleeding to death who
might benefit from bleeding less. By way of analogy, al-
though cholesterol reduction is the mechanism by which
statins reduce the risk of myocardial infarction, this does
not mean that statins should only be used in patients
with high cholesterol levels. Statins also reduce the risk
of myocardial infarction in patients with ‘normal’ choles-
terol levels [23]. Treatment decisions should be based
on the risk of the adverse outcome (prognosis) rather
than an arbitrary diagnosis based on a single parameter.
Since TXA is highly cost-effective, with no serious side
effects, it could be used in all trauma patients at risk of
bleeding to death [24].
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Conclusions
When generalising results from clinical trials, biological
insight into the mechanism of action of the treatment
and an awareness of the circumstances in which a find-
ing applies are more relevant to patient care than the ap-
plication of statistical reasoning. A deeper consideration
of biological mechanisms should also result in wider rec-
ognition that the risk ratio is the generalizable measure
of the treatment effect and that differential subgroup
effects should be viewed with scepticism.
The ultimate aim of therapeutic research is to formu-
late general conclusions about the effects of medicines
that can inform the management of different patients, in
different places and different times. This process of sci-
entific inference is greatly aided by results from studies
that rigorously control bias and random error, which
usually implies randomisation of large numbers of pa-
tients (thus providing large numbers of outcome events).
It is not necessary, however, that the trial population is
representative of the population in which the medicine
will be used.
On the other hand, statistical inference, the process of
using sample information to reach conclusions about the
population from which it was drawn, is helped by having
a representative sample. If we wanted to know what
proportion of trauma patients received TXA, we might
conduct a survey in a representative sample of trauma
patients. The results would apply to a specific location
at a particular time. The reluctance to generalise treat-
ment effects on the basis of representativeness confuses
scientific and statistical inference [6]. It is important to
emphasise that we do believe that further trials of TXA
in trauma patients are needed. However, future trials
should aim to extend our knowledge of the effects of
TXA and should therefore address important biologic-
ally based treatment uncertainties.
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